Roger McIntyre – Psilocybin-based Therapies in Mood Disorders
TouchNEUROLOGY caught up with Roger McIntyre (University Toronto, Ontario, Canada) to discuss psychedelics, and in particular psilocybin-based therapies, and their potential in the treatment of mood disorders.
1. Please could you give us a brief overview of psilocybin and its action on serotonergic (5-HT) pathways? (0:04)
2. Which conditions are most likely to benefit from psilocybin therapy? (0:48)
3. What are the major challenges in bringing psilocybin-based products to the market? (1:57)
4. Could you tell us a little about the products you are working with and the current research activities? (3:18)
5. What will be the next steps in the development of psilocybin-based therapies? (4:38)
Speaker Disclosure: Roger McIntyre has acted as a consultant and/or received research support from Lundbeck, Janssen, Shire, Purdue, Pfizer, Otsuka, Allergan, Takeda, Neurocrine, Sunovion, Minerva, Intra-Cellular Pharmaceuticals, Stanley Medical Research Institute, and CIHR/GACD/National Natural Science Foundation of China. He is CEO of Champignon, which acquired the Canadian Rapid Treatment Centre of Excellence.
Support: Interview and filming supported by Touch Medical Media.
Share this Video
Related Videos In Psychiatric Disorders
Discovery of ketamine to treat psychiatric disorders targeting monoamine signaling: John Krystal, APA 2023
The discovery of ketamine’s therapeutic potential for psychiatric disorders changed the field of mental health, since nearly every FDA-approved medication for schizophrenia and mood disorders targeted monoamine signaling, i.e., dopamine, serotonin, and norepinephrine. As ketamine was initially used as an anaesthetic, ketamine’s ability to modulate monoamine signaling pathways emerged, leading to ground-breaking breakthroughs. In this […]
Ketamine’s therapeutic potential for psychiatric disorders: John Krystal, APA 2023
The discovery of the rapid antidepressant effects of ketamine shifted the biology and treatment of psychiatric disorders, emphasizing targeting glutamate signaling, rather than monoamine signaling, for schizophrenia and depression. Research highlights synaptic deficits, network disinhibition, and synaptic loss in schizophrenia, while identifying glutamate synaptic dysfunction and the efficacy of ketamine for depression. In this touchNEUROLOGY […]
Hannu Alho – Potential of Ondansetron in Alcohol Use Disorder (Part 1)
Professor Emeritus of Addiction Medicine, Hannu Alho (University of Helsinki, Finland) discusses the need for effective treatment options to manage alcohol use disorder, focusing on odansetron as a newly emerging possibility. Ondansetron is a specific 5HT3-receptor antagonist, which blocks 5HT3 receptors in the gastrointestinal tract and central nervous system, and has been used since the […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!